EnzymeRx. LLC
EnzymeRx Announces Receipt of $14 million Capital Investment and Acquisition of Pegylated Uricase
Published in Cancer Weekly, June 10th, 2008
EnzymeRx, a clinical stage biotechnology company, announced it has raised $14 million from funds managed by Pequot Capital Management and has acquired worldwide rights, excluding Taiwan, to uricase-PEG 20 from Polaris Pharmaceuticals, which will also hold an equity stake in EnzymeRx. Uricase-PEG 20 is a pegylated form of the enzyme uricase (urate oxidase) that has previously completed a single dose phase I trial and is being developed for the treatment of refractory gout and tumor lysis syndrome. Plans for additional clinical studies, including a multi-dose phase II study in refractory gout patients, are under way.
EnzymeRx's President and Chief Executive Officer Tony...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-06-10)
More Articles from Cancer Weekly
- Brain Cancer
St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors - Cancer
BiPar Sciences Expands Clinical Development of BSI-201, a Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer - Cancer
Mobile Phones: More Dangerous Than Smoking - Cancer Vaccines
Data on cancer vaccines detailed by M.E. Engelhorn and co-authors - Cancer Vaccines
Recent findings from Mayo Clinic highlight research in cancer vaccines - Cyclacel Pharmaceuticals, Inc.
Vall d'Hebron University Hospital and Cyclacel to Initiate Phase 1 Combination Study of Seliciclib and Tarceva in Advanced Cancers - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
